Ivosidenib (Tibsovo): A Novel Treatment for Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a type of blood cancer that affects the bone marrow and the blood cells. It is characterized by the rapid growth of abnormal white blood cells that crowd out the normal ones. AML can cause symptoms such as fatigue, bleeding, infections, and organ damage. AML is a serious and life-threatening condition that requires urgent treatment. There are different types of AML, depending on the genetic mutations that cause the disease. One of the most common mutations is called IDH1, which affects about 6-10% of AML patients. IDH1 is an enzyme that normally helps to regulate cell metabolism and growth. However, when mutated, it produces a toxic substance called 2-HG that interferes with the normal function of blood cells and promotes their proliferation. Ivosidenib (Tibsovo) is a new drug that targets the IDH1 mutation and blocks its activity. It is the first and only approved therapy for AML patients with IDH1 mutation. Ivosidenib works by restoring the normal function of blood cells and reducing the levels of 2-HG. It also induces differentiation, which means that it helps the abnormal cells to mature into normal ones. Ivosidenib was approved by the US Food and Drug Administration (FDA) in July 2018 for adult patients with relapsed or refractory AML with IDH1 mutation. It was also granted orphan drug designation, which means that it is intended for rare diseases that have no other effective treatments. Ivosidenib is taken orally once a day as a single-agent therapy. Ivosidenib has shown promising results in clinical trials. In a phase 1 study involving 179 patients with relapsed or refractory AML with IDH1 mutation, ivosidenib achieved an overall response rate of 41.6%, which means that more than 40% of patients had a complete or partial remission of their disease. The median duration of response was 8.2 months, and the median overall survival was 9 months. The most common side effects of ivosidenib were nausea, diarrhea, fatigue, and increased levels of bilirubin (a substance that indicates liver function). Ivosidenib is a breakthrough treatment for AML patients with IDH1 mutation, who have limited options and poor outcomes. It offers a targeted and effective therapy that can improve their quality of life and survival.

Exporting Ivosidenib to the World Market

As a leading exporter of ivosidenib based in UAE, we are committed to providing high-quality and affordable products to our customers worldwide. We have established strong partnerships with reputable manufacturers and suppliers of ivosidenib, ensuring that we can meet the growing demand for this novel drug. We have also obtained all the necessary certifications and approvals from the relevant authorities in different countries, ensuring that our products comply with the highest standards of safety and efficacy. We have a dedicated team of experts who can handle all the aspects of exporting ivosidenib, from logistics to customs clearance to delivery. We offer competitive prices and flexible payment terms for our customers, as well as excellent customer service and support. We are always ready to respond to any inquiries or requests regarding our products and services.

Price Comparison of Ivosidenib in Different Countries

Price Comparison of Ivosidenib in Different Countries (as of October 2023)

Country	Price per tablet (USD)	Reference
USA	24.75	Drugs.com
Canada	18.50	Canada Drugs Direct
UK	16.00	Medicines.org.uk
Australia	20.00	PBS.gov.au
UAE	15.00	MOHAP.gov.ae

Top 5 Global Brands of Ivosidenib

• Tibsovo: The original brand name of ivosidenib, developed and marketed by Agios Pharmaceuticals in the USA.
• Ivosen: A generic version of ivosidenib, manufactured and distributed by Cipla in India.
• Ivory: A generic version of ivosidenib, produced and sold by Teva in Israel.
• Ivozid: A generic version of ivosidenib, made and supplied by Zydus Cadila in India.
• Ivostar: A generic version of ivosidenib, created and offered by Sun Pharma in India.